Are lorlatinib and lorlatinib the same drug name?

Lorlatinib and lorlatinib are actually different names for the same drug. Lorlatinib is the international common English name of the drug, while "lorlatinib" and "lorlatinib" are its different transliterations in the Chinese context. This phenomenon is relatively common in drug naming. Due to differences in different regions or translators' habits, drug names may have slight spelling or pronunciation differences, but they essentially refer to the same chemical entity.

As a third-generation ALK (anaplastic lymphoma kinase) and ROS1 inhibitor, lorlatinib is mainly used to treat patients with ALK positive non-small cell lung cancer, especially for patients who are resistant to early ALK inhibitors or have brain metastases. Its pharmacological effects and clinical applications are completely consistent with those of lorlatinib, and there are no differences between the two in terms of efficacy, indications, usage and dosage, and side effects.

In clinical practice and drug procurement, sometimes the two names "lorlatinib" or "lorlatinib" coexist according to the registration name or marketing application of the drug regulatory authorities in different regions. However, this different naming will not affect the safety and efficacy of the drug for patients. Doctors and patients should pay attention to the approval number and manufacturer of the drug when using it, and ensure that they purchase compliant drugs from formal channels.

In short, lorlatinib and lorlatinib are different names for the same drug. There is no essential difference between the two. They both point to the third generation ALK inhibitorLorlatinib. Understanding this can help avoid misunderstandings caused by name differences and promote rational clinical use of drugs and accurate communication of drug information.

Reference materials:https://www.drugs.com/

xa0